Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 4 Interventional

Effect of Detrol LA on Overactive Bladder Symptoms, Sexual Quality of Life and Sexual Function in Women

ClinicalTrials.gov ID: NCT00143481

Public ClinicalTrials.gov record NCT00143481. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Jul 23, 2026, 11:13 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Multi-Center, Double-Phase, Randomized, Double-Blind, Placebo Controlled (12-Week Double-Blind Followed by 12-Week Open-Label) Study Evaluating the Effect of Tolterodine ER on Urgency Urinary Incontinence (UUI), Urgency, Frequency, Sexual Quality of Life and Sexual Function in Women With Overactive Bladder

Study identification

NCT ID
NCT00143481
Recruitment status
Completed
Study type
Interventional
Phase
Phase 4
Lead sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Industry
Enrollment
400 participants

Conditions and interventions

Interventions

  • Tolterodine ER 4mg QD Drug

Drug

Eligibility (public fields only)

Age range
18 Years and older
Sex
Female
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Feb 28, 2005
Primary completion
May 31, 2006
Completion
Not listed
Last update posted
Jan 26, 2021

Started 2005

United States locations

U.S. sites
58
U.S. states
24
U.S. cities
49
Facility City State ZIP Site status
Pfizer Investigational Site Chandler Arizona 85225
Pfizer Investigational Site Phoenix Arizona 85013
Pfizer Investigational Site Little Rock Arkansas 72205
Pfizer Investigational Site Berkeley California 94705
Pfizer Investigational Site Oakland California 94612
Pfizer Investigational Site San Diego California 92108
Pfizer Investigational Site San Francisco California 94102
Pfizer Investigational Site Santa Rosa California 95405
Pfizer Investigational Site Denver Colorado 80202
Pfizer Investigational Site Denver Colorado 80204
Pfizer Investigational Site Lakewood Colorado 80228
Pfizer Investigational Site Farmington Connecticut 06032
Pfizer Investigational Site West Hartford Connecticut 06117
Pfizer Investigational Site Clearwater Florida 33759
Pfizer Investigational Site Leesburg Florida 34748
Pfizer Investigational Site Miami Florida 33145
Pfizer Investigational Site Pembroke Pines Florida 33024
Pfizer Investigational Site West Palm Beach Florida 33409-1972
Pfizer Investigational Site Weston Florida 33331
Pfizer Investigational Site Alpharetta Georgia 30005
Pfizer Investigational Site Evansville Indiana 47714
Pfizer Investigational Site Newburgh Indiana 47630
Pfizer Investigational Site South Bend Indiana 46601
Pfizer Investigational Site Baton Rouge Louisiana 70815
Pfizer Investigational Site Metairie Louisiana 70002
Pfizer Investigational Site Metairie Louisiana 70006
Pfizer Investigational Site Baltimore Maryland 21211
Pfizer Investigational Site Saginaw Michigan 48602
Pfizer Investigational Site Creve Coeur Missouri 63141
Pfizer Investigational Site Las Vegas Nevada 89109
Pfizer Investigational Site Las Vegas Nevada 89128
Pfizer Investigational Site North Las Vegas Nevada 89030
Pfizer Investigational Site New Brunswick New Jersey 08901
Pfizer Investigational Site Albuquerque New Mexico 87131-0001
Pfizer Investigational Site Olean New York 14760
Pfizer Investigational Site New Bern North Carolina 28562
Pfizer Investigational Site Winston-Salem North Carolina 27103
Pfizer Investigational Site Cincinnati Ohio 45220
Pfizer Investigational Site Cincinnati Ohio 45267
Pfizer Investigational Site Cleveland Ohio 44122
Pfizer Investigational Site Cleveland Ohio 44195
Pfizer Investigational Site Columbus Ohio 43213
Pfizer Investigational Site Gallipolis Ohio 45631
Pfizer Investigational Site Allentown Pennsylvania 18104
Pfizer Investigational Site Philadelphia Pennsylvania 19114
Pfizer Investigational Site Columbia South Carolina 29201
Pfizer Investigational Site Austin Texas 78703
Pfizer Investigational Site Austin Texas 78705
Pfizer Investigational Site Austin Texas 78756
Pfizer Investigational Site Bryan Texas 77802-1903
Pfizer Investigational Site Conroe Texas 77304
Pfizer Investigational Site Irving Texas 75061
Pfizer Investigational Site San Antonio Texas 78229
Pfizer Investigational Site Salt Lake City Utah 84107
Pfizer Investigational Site Salt Lake City Utah 84124
Pfizer Investigational Site Seattle Washington 98105
Pfizer Investigational Site Morgantown West Virginia 26505
Pfizer Investigational Site Morgantown West Virginia 26506-9251

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT00143481, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Jan 26, 2021 · Synced Jul 23, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT00143481 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →